Previous close | 0.7175 |
Open | 0.6700 |
Bid | 0.7059 x 100 |
Ask | 0.7719 x 100 |
Day's range | 0.6500 - 0.7500 |
52-week range | 0.1650 - 3.8400 |
Volume | |
Avg. volume | 1,612,518 |
Market cap | 7.376M |
Beta (5Y monthly) | -0.79 |
PE ratio (TTM) | N/A |
EPS (TTM) | -6.2500 |
Earnings date | 28 Mar 2024 - 02 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
David Lazar invests $3 million in Preferred StockNew OpGen Board of Directors appointedDavid Lazar will take over as CEO of OpGenOpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred St
Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022Implemented certain cash management initiatives, including restructuring U.S. operations by reducing headcount during the third quarter of 2023Signed preferred stock purchase agreement with a potential strategic investor in October 2023Entered into a warrant inducement agreement with an institutional investor in October 2023Subsidiaries Curetis G
Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics are part of the Zacks Screen of the Week article.